不同剂量阿托伐他汀对冠心病介入术后患者心功能、血脂指标的影响及其安全性评价

摘要
图/表
参考文献(15)
相关文章 (15)

全文: PDF (0 KB) HTML (32 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨不同剂量阿托伐他汀对冠心病介入术后患者心功能、血脂指标的影响及安全性。方法选取2015年1～12月我院收治的100例行经皮冠状动脉介入术治疗的冠心病患者，采用随机数字表法分为常规剂量组和大剂量组，各50例。两组患者术后均给予阿托伐他汀治疗，常规剂量组：20 mg/（次·d），大剂量组：40 mg/（次·d），均连续用药1个月。比较两组患者的心功能、血脂指标及用药安全性。结果治疗前，两组患者的各项心功能指标差异无统计学意义（P＞0.05），治疗后，大剂量组患者的左室收缩末期容积指数（LVESVI）、左室舒张末期容积指数（LVEDVI）显著低于常规剂量组，左室射血分数（LVEF）显著高于常规剂量组，差异均有统计学意义（P＜0.05）。治疗前，两组患者的各项血脂指标差异无统计学意义（P＞0.05），治疗后，大剂量组患者的总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）显著低于常规剂量组，差异有统计学意义（P＜0.05）。大剂量组患者出现头晕1例，消化道反应2例，尿素氮升高1例，总不良反应发生率为8.0%，常规剂量组患者出现头晕1例，消化道反应1例，尿素氮升高1例，总不良反应发生率为6.0%，两组的总不良反应发生率差异无统计学意义（P＞0.05）。结论冠心病患者介入术后应用阿托伐他汀可有效改善心功能及血脂指标，大剂量应用的疗效更佳，且安全性较好，值得临床推广应用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	蒋羽
	毕卉

关键词 ：冠心病, 介入手术, 阿托伐他汀, 剂量, 心功能, 血脂

Abstract：Objective To study the effect of different doses of Atorvastatin on cardiac function and blood lipid index in patients with coronary artery disease(CAD)after coronary intervention as well as their safety.Methods 100 patients with CAD undergone percutaneous coronary intervention(PCI)in our hospital from January to December 2015 were selected as research objects.By a random number table method,they were randomly divided into conventional(n=50)and highdose group(n=50).After surgery,they were both provided with Atorvastatin at a dose of 20 mg once per day(conventional dose group)and 40 mg once per day(high dose group).The course of treatment was lasted for one month.The cardiac function,blood lipid and drug safety between the two groups were compared.Results Before treatment,there was no difference in each index of cardiac function between the two groups(P＞0.05).After therapy,the left ventricular end systolic volume index(LVESVI)and left ventricular end diastolic volume index(LVEDVI)in the high dose group were both significantly lower than those in the conventional dose group,the left ventricular ejection fraction(LVEF)was higher in comparison with that in the conventional dose group,which were all displayed statistical difference(P＜0.05).No difference was found in each index of blood lipid before treatment in both groups(P＞0.05).After PCI,the total cholesterol (TC)and low density lipoprotein cholesterol(LDL-C)were both obviously lower than those in the conventional dose group with statistical difference(P＜0.05).With regards to adverse reactions,there were vertigo in one case,digestive tract reaction in two cases,and increase of urea nitrogen in one case in the high dose group,and the total incidence of adverse reactions was 8.0%.In the conventional dose group,one case was occurred with vertigo,one was digestive tract reaction, and one case with the increase of urea nitrogen.The total incidence of adverse reactions was 6.0%,which was not displayed difference after comparison(P＞0.05).Conclusion Atorvastatin can effectively improve cardiac function and blood lipid index after PCI in patients with CAD.The effect is better if used in a high dose of the drug with better safety, which is worthy of clinical promotion and application.

Key words： Coronary heart disease;Interventional surgery Atorvastatin;Dose;Cardiac function;Blood lipid

作者简介: 蒋羽（1981-），男，安徽巢湖人，主管药师，主要从事药学方面的研究

引用本文:

蒋羽；毕卉. 不同剂量阿托伐他汀对冠心病介入术后患者心功能、血脂指标的影响及其安全性评价[J]. 中国当代医药, 2017, 24(3): 104-106.
JIANG Yu；BI Hui. Influence of different doses of Atorvastatin on cardiac function and blood lipid index in patients with coronary artery disease after percutaneous coronary intervention and their safety evaluation. 中国当代医药, 2017, 24(3): 104-106.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2017/V24/I3/104

[1]	张文，张勤斌，胡大清.大剂量阿托伐他汀用于冠状动脉旁路移植术临床观察[J].中国药师，2011，14（7）：1021-1022.
[2]	马文学，彭剑峰，江志羔，等.应用64排CT评价两种剂量阿托伐他汀对急性冠脉综合征PCI术后冠状动脉斑块的影响[J].中国当代医药，2013，20（19）：26-28.
[3]	李春香，万大国.阿托伐他汀在急性冠脉综合征治疗中的应用[J].河南医学研究，2010，19（4）：419-421.
[6]	谢进，李欣，许臣洪，等.PCI围术期阿托伐他汀强化治疗对冠心病患者术后再狭窄的影响[J].四川医学，2012，33（6）：989-991.
[7]	Vrints CJ.Pathophysiology of the no reflow phenomenon[J]. Acute Card Care，2013，11（2）：69-76.
[4]	Schoonjans K，Peinado-Onsurbe J，Fruchart JC，et al.3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-Ⅲand lipoprotein lipase[J].FEBS Lett，2014，452（3）：160-164.
[5]	Landmesser U，Bahlmann F，Mueller M，et al.Simvastatin versus ezetimibe：pleiotropic and lipid-lowering effects on endothelial function in humans[J].Circulation，2015，111（18）：2356-2363.
[8]	张文利，黄定.PCI术后冠状动脉再狭窄机制及防治研究进展[J].中国循证心血管医学杂志，2011，3（2）：154-156.
[9]	汤达鹏，刘凌华，陈涛，等.不同剂量阿托伐他汀在冠脉介入治疗围手术期的应用研究[J].海南医学院学报，2012，18（6）：830-832.
[10]	王震宇，禹同生，王健，等.阿托伐他汀的药理作用及临床应用进展[J].中国新药杂志，2010，19（18）：25-27.
[11]	叶广宁，欧家满，黄万里.不同剂量阿托伐他汀对冠心病介入治疗患者血脂的影响[J].齐齐哈尔医学院学报，2012，33（3）：313-314.
[12]	Davignon J.Beneficial cardiovascular pleiotropic effects of statins[J].Circulation，2014，109（23）：39-43.
[13]	高慧文，李可莉.阿托伐他汀对原发性高血压患者血脂及心功能的影响研究[J].疑难病杂志，2012，11（7）：2472-2473.
[14]	Cho YK，Hur SH，Han CD，et al.Comparison of ezetimibe/ simvastatin 10/20mg versus atorvastatin 20mg in achieving a target low density lipoprotein-cholesterol goal for patients with very high risk[J].Korean Circ J，2011，41（3）：149-153.
[15]	Grundy SM，Cleeman JI，Merz CN，et al.Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment PanelⅢGuidelines[J].J Am Coll Cardiol，2014，44（3）：720-732.